Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD476 dose-ranging study in mild to moderate ulcerative colitis
NCT00545389Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2003
- Primary completion
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Salcrozine in ulcerative colitis (UC) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of subjects in remission (UC-DAI score) at 8 weeks. Started Feb 2003; status: completed.
02
Drugs
Salcrozine
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT00545389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00545389.